Agenus and ChemRar Sign License Deal
Under the agreement, Agenus has granted NewVac an exclusive license to manufacture, market and sell its Oncophage (HSPPC-96; vitespen) vaccine as well as pursue a development program of Oncophage in combination with NewVacâ€™s co-adjuvant technology in the Russian Federation and CIS countries.
Agenus is entitled to receive a transfer price and/or royalties upon Oncophage product sales, and potential milestone payments.
Garo Armen, chairman and CEO of Agenus, said: â€œWe are very excited to work with NewVac as an innovative scientific partner that is ready to both establish an Oncophage manufacturing facility in Russia and to commercialize this unique personalized cancer vaccine.
â€œIn addition, the planned development efforts for Oncophage in combination with NewVac's co-adjuvant will provide us with an opportunity to explore how Oncophage can contribute even more to patient care. This agreement brings us a step closer to making this product available to patients and driving further innovation in the cancer immunotherapy field.â€
Nikolay Savchuk, chairman of the board of NewVac, said: â€œOur goal is to create an innovative world-class biomedical platform for the treatment of oncologic diseases based on immunotherapeutic approaches in Russia.â€
Oncophage was approved in Russia in 2008 for the treatment of renal cell carcinoma (RCC; kidney cancer) in patients at intermediate risk of recurrence.
Renal cell carcinoma (RCC) is the most common type of kidney cancer accounting for almost 90 percent of all kidney tumors.
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.